EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 10

Jatamansi (spikenard) Nardostachys jatamansi (D.Don) DC.

Also called: spikenard, Indian spikenard, muskroot, Nardostachys grandiflora (synonym), Nardostachys chinensis (synonym)

Jatamansi is a small rhizomatous perennial of the alpine Himalaya; its rhizome is used in Ayurvedic, Unani, Chinese and Tibetan medicine. The plant is critically endangered and CITES-listed, and human trials are few and small.

Category
Botanical
Part used
Rhizome
Strongest evidence
C Limited
Native range
Native from the Himalaya to western and central China and northern Myanmar (POWO: "Himalaya to W. & Central China and N. Myanmar")
Reviewed
2026-10-29

Class 3 Limited studies in people. No review was found. This entry cites 1 RCT of jatamansi alone (source 4: 40 adults, versus placebo) and 1 comparison with valerian in 30 patients that describes random selection but not how groups were allocated (source 5). [4]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

2 topics studied2 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Jatamansi (spikenard) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Jatamansi (spikenard), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Blood pressure in stage 1 hypertensionCIn a single-blind RCT of 40 adults, 3 g/day for 4 weeks lowered mean blood pressure from about 144/95 to 134/83 mmHg, while placebo produced no significant change. [4]
Primary insomniaCIn a non-placebo comparison (patients described as randomly selected; group allocation not stated), 15 patients given jatamansi powder 4 g three times daily for a month improved on sleep measures, but less than patients given valerian (Valeriana wallichii). [5]

Main constituents: Terpenoids and phenolic compounds are the main constituents reported in the genus Nardostachys; sesquiterpenoids are the major bioactive components [1]; Jatamansone is among the named constituents [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 3 g/day (one capsule three times a day) for 4 weeks (hypertension RCT). [4]
  • Jatamansi powder (churna) 4 g with milk three times a day for 1 month (insomnia comparative study). [5]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • A genus-level review reports that in vivo and in vitro toxicology studies found no or low toxicity for Nardostachys plants, except at high doses. [1]
  • Another review lists the absence of toxicology studies in animal models and of clinical trials in humans among the limitations of N. jatamansi research. [3]
Quality

Identity, quality and standardization

  • Nardostachys jatamansi and Valeriana jatamansi share vernacular names, and many studies on dried samples may not have used the species named; reviewers call for molecular and chemical authentication markers. [3]
  • Published quality methods for Nardostachys include TLC/HPTLC, GC and HPLC/UPLC with PDA, DAD or MS detection. [1]
Regulation

Regulatory status

  • International trade: CITES Appendix II (current listing in effect since 13 September 2007; originally listed as Nardostachys grandiflora, now a synonym), annotation #2: all parts and derivatives except seeds and pollen, and finished products packaged and ready for retail trade. [8]
  • US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [9]
  • US: No NDI notification naming jatamansi (Nardostachys jatamansi) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [10]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Sesquiterpenoids (major bioactive components in the genus Nardostachys) Terpenoids (sesquiterpenoids) [P1]
  • Jatamansone (valeranone) Sesquiterpenoid [P11]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming jatamansi (Nardostachys jatamansi) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of jatamansi (Nardostachys jatamansi) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P4]
  • NTP technical reports list checked 2026-10-29: no report on Nardostachys found. [P5]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • Dhiman and Bhattacharya (2020) found that Nardostachys jatamansi and Valeriana jatamansi share vernacular names, and that the phytochemical profiles reported for dried samples suggest the two species may have been confused. [P6]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test of the dietary ingredient (at least one appropriate test or examination before use) — 21 CFR 111.75(a)(1)(i) requires identity verification of every component that is a dietary ingredient, unless FDA exempts the firm on petition under 111.75(a)(1)(ii). [P7]
  • Species authentication excluding Valeriana jatamansi (molecular and chemical markers) — The two species share vernacular names and have been confused in studies (Dhiman and Bhattacharya 2020). [P6]
  • Chemical profile (TLC/HPTLC, GC or HPLC/UPLC) — Methods reviewed for qualitative and quantitative analysis of Nardostachys constituents (Wang et al. 2021). [P1]

Supply and conservation

  • IUCN Red List: Critically Endangered (CR), via GBIF species API, retrieved 2026-10-29. [P8]
  • CITES Appendix II (current listing in effect since 13 September 2007; originally listed as Nardostachys grandiflora, now a synonym), annotation #2: all parts and derivatives except seeds and pollen, and finished products packaged and ready for retail trade. [P9]
  • The plant is critically endangered and found in alpine and sub-alpine regions of the Himalayas (Dhiman and Bhattacharya 2020). [P6]
  • India lists Nardostachys jatamansi among 13 medicinal plants receiving a 75% cultivation-cost subsidy. [P10]

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Wang M, et al. A review on traditional uses, phytochemistry, pharmacology, toxicology and the analytical methods of the genus Nardostachys. J Ethnopharmacol 2021;280:114446 (PMID 34339792), 2021-11-15. pubmed.ncbi.nlm.nih.gov
  2. Pathak S, Godela R. Nardostachys jatamansi: phytochemistry, ethnomedicinal uses, and pharmacological activities: a comprehensive review. Fitoterapia 2024;172:105764 (PMID 38042505), 2024-01. pubmed.ncbi.nlm.nih.gov
  3. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  4. IARC Monographs. Agents classified by the IARC Monographs (list of classifications, checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  5. National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  6. Dhiman N, Bhattacharya A. Nardostachys jatamansi (D.Don) DC. - challenges and opportunities of harnessing the untapped medicinal plant from the Himalayas. J Ethnopharmacol 2020;246:112211 (PMID 31533076), 2020-01-10. pubmed.ncbi.nlm.nih.gov
  7. eCFR. 21 CFR 111.75 (current as of October 27, 2026), 2026-10-27. ecfr.gov
  8. GBIF species API: IUCN Red List category for Nardostachys jatamansi, 2026-10-29. api.gbif.org
  9. UNEP-WCMC / CITES Secretariat. Species+: Nardostachys jatamansi, CITES listing (retrieved 2026-10-29), 2026-10-29. speciesplus.net
  10. Anmol, et al. Ethnopharmacologically important highly subsidized Indian medicinal plants: systematic review on their traditional uses, phytochemistry, pharmacology, quality control, conservation status and future prospective. J Ethnopharmacol 2024;320:117385 (PMID 37951375), 2024-02-10. pubmed.ncbi.nlm.nih.gov
  11. EMBL-EBI ChEBI. Valeranone (CHEBI:80748), is a sesquiterpenoid (retrieved 2026-10-29); PubChem CID 10198387 lists jatamansone as a synonym, 2026-10-29. ebi.ac.uk
Sources

Sources

  1. Wang M, et al. A review on traditional uses, phytochemistry, pharmacology, toxicology and the analytical methods of the genus Nardostachys. J Ethnopharmacol 2021;280:114446 (PMID 34339792), 2021-11-15. pubmed.ncbi.nlm.nih.gov
  2. Pathak S, Godela R. Nardostachys jatamansi: phytochemistry, ethnomedicinal uses, and pharmacological activities: a comprehensive review. Fitoterapia 2024;172:105764 (PMID 38042505), 2024-01. pubmed.ncbi.nlm.nih.gov
  3. Dhiman N, Bhattacharya A. Nardostachys jatamansi (D.Don) DC. - challenges and opportunities of harnessing the untapped medicinal plant from the Himalayas. J Ethnopharmacol 2020;246:112211 (PMID 31533076), 2020-01-10. pubmed.ncbi.nlm.nih.gov
  4. Bhat MDA, Malik SA. Efficacy of Nardostachys jatamansi (D.Don) DC in essential hypertension: a randomized controlled study. Complement Ther Med 2020;53:102532 (PMID 33066862), 2020-09. pubmed.ncbi.nlm.nih.gov
  5. Toolika E, et al. A comparative clinical study on the effect of Tagara (Valeriana wallichii DC.) and Jatamansi (Nardostachys jatamansi DC.) in the management of Anidra (primary insomnia). Ayu 2015;36(1):46-9 (PMID 26730138), 2015-01. pubmed.ncbi.nlm.nih.gov
  6. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Nardostachys jatamansi (D.Don) DC. (accessed 2026-10-29; Kew cannot warrant the accuracy of the data), 2026-10-29. powo.science.kew.org
  7. World Checklist of Vascular Plants (WCVP), Darwin Core archive, GBIF dataset f382f0ce-323a-4091-bb9f-add557f3a9a2 (published 2026-06-04): synonym records, 2026-06-04. gbif.org
  8. UNEP-WCMC / CITES Secretariat. Species+: Nardostachys jatamansi, CITES listing (retrieved 2026-10-29), 2026-10-29. speciesplus.net
  9. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  10. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.